VANGL2 and metastatic neoplasm: Analysis of lung tissue revealed that deletion of Vangl2 in MMTV-NDL tumors results in significantly reduced frequency of metastatic disease (Fig. 6b), number of lung metastases (Fig. 6c), and overall metastatic burden (Fig. 6d) despite similar primary tumor characteristics such as numbers of palpable tumors (Fig. 6e), total tumor volume (Fig. 6f), average tumor volume (Fig. 6g), tissue histology (Additional file 4: Fig. S9e–f), proliferative capacity (Additional file 4: Fig. S9 g-h), and apoptosis (Additional file 4: Fig. S9i–j).